Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28515 | 0.84 | CTSL (0.43) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL44259 | 0.83 | IDO1 (0.44) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL19514760 | 0.79 | CA12 (0.43) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL11384559 | 0.79 | CYP1A2 (0.42) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL9217746 | 0.79 | MAOB (0.44) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL10978005 | 0.79 | CYP1A2 (0.42) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL1679996 | 0.79 | IDO1 (0.41) | IDO1NOS3NOS1NOS2MAOB | |
| Benzyl Thiocyanate SCHEMBL129196 | 0.79 | MAOB (0.48) | IDO1NOS3NOS1NOS2MAOB | |
| Benzyl Thiocyanate SCHEMBL11858619 | 0.77 | MAOB (0.47) | IDO1NOS3NOS1NOS2MAOB | |
| Benzyl Thiocyanate SCHEMBL21114375 | 0.74 | MAOA (0.41) | IDO1NOS3NOS1NOS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081452-A1 | POLYDIENES AND DIENE COPOLYMERS USING 1,1-BIS(HYDROCARBYLTHIO)HYDROCARBYL-1-ENE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2221309-B1 | NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | TOYAMA CHEMICAL CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8354426-B2 | Naphthyridine derivative monohydrate and method for producing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20100152456-A1 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-06-17 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2008-11-27 | — | — | US | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1857456-A1 | PROCESS FOR PRODUCING COMPOUND WITH ANTI-HCV POTENCY AND INTERMEDIATE FOR USE THEREIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | HCCS, EIF2AK2, MAVS | IDO1 1119/4885NOS3 935/4885NOS1 905/4885 |
| US-20100152456-A1 | Intermediate compound for synthesis of viridiofungin a derivative | ZC3HAV1, ZC3HAV1L, MAVS | IDO1 1101/4885NOS3 1862/4885NOS1 1892/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | IDO1 1168/4885NOS3 1033/4885NOS1 384/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | IDO1 261/4885NOS3 1870/4885NOS1 1994/4885 |
| US-20030158164-A1 | Novel antiandrogenic agent | NR5A1, CYP19A1, HSD17B11 | IDO1 4660/4885NOS3 3106/4885NOS1 2446/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | IDO1 243/4885NOS3 1599/4885NOS1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.